FDA approves world’s first dual-sensor CGM in diabetes 'breakthrough' — new Libre Duo sensor tracks ketones and blood sugar in real-time

https://cdn.mos.cms.futurecdn.net/fFVLZDuyDxjBzSATQtMHoD-1920-80.jpg
  • The FDA has approved the Libre Duo 10 Day CGM wearable
  • It can continuously measure both ketones and blood sugar levels
  • It’s worn by diabetics as a continuous glucose monitor (CGM)

The US Food and Drug Administration (FDA) has approved the first wearable device capable of simultaneously monitoring both ketone and bloody sugar levels, which the organization says is “a breakthrough for the safety of children and adults living with diabetes".

The device in question is the Libre Duo 10 Day monitor. Worn on your arm as a continuous glucose monitor (CGM), it provides minute-by-minute glucose updates that are sent to your smartphone. It also monitors ketone levels and sends you an alert if they rise above a certain threshold.

In terms of who can use it, the Libre Duo 10 Day wearable has been approved for use by people aged two or over who are living...

Copyright of this story solely belongs to techradar.com. To see the full text click HERE

Read more

https://d2908q01vomqb2.cloudfront.net/f1f836cb4ea6efb2a0b1b99f41ad8b103eff4b59/2026/10/14/ML-21817-featured-image.png

Beyond the KV cache: Training and serving i14’s Laplace 3B linear attention model on AWS Trainium2 with native PyTorch | Amazon Web Services

Most large language models (LLMs) use transformer architectures with softmax attention. During inference, their key-value (KV) cache grows with the conversation or document context. This can reduce concurrency, increase serving cost, and force agentic applications to discard useful history. i14 designed Laplace 3B as a linear attention alternative. Its recurrent